SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$30.12

06 Dec
2023

0.750

OPEN

$29.27

2.55%

HIGH

$30.21

1,292,026

LOW

$29.26

TARGET
$34.458 14.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 145.8 138.1 xxx
DPS (cps) xxx 104.0 104.1 xxx
EPS Growth xxx - 52.3% - 5.3% xxx
DPS Growth xxx 4.0% 0.1% xxx
PE Ratio xxx N/A 22.1 xxx
Dividend Yield xxx N/A 3.4% xxx
Div Pay Ratio(%) xxx 71.3% 75.4% xxx

Dividend yield today if purchased 3 years ago: 3.28%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.41

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 62c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx145.8
DPS All xxxxxxxxxxxxxxx104.0
Sales/Revenue xxxxxxxxxxxxxxx7,964.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,643.2
Net Operating Cash Flow xxxxxxxxxxxxxxx1,471.0 M
Net Profit Margin xxxxxxxxxxxxxxx8.60 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx9.13 %
Return on Invested Capital xxxxxxxxxxxxxxx6.70 %
Return on Assets xxxxxxxxxxxxxxx5.14 %
Return on Equity xxxxxxxxxxxxxxx9.13 %
Return on Total Capital xxxxxxxxxxxxxxx7.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx601.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx347 M
Long Term Debt xxxxxxxxxxxxxxx2,754 M
Total Debt xxxxxxxxxxxxxxx3,100 M
Goodwill - Gross xxxxxxxxxxxxxxx7,336 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx798 M
Price To Book Value xxxxxxxxxxxxxxx2.16

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx497.0 M
Capex % of Sales xxxxxxxxxxxxxxx6.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx5,851 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,294 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx176 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

21/08/2023

1

Add

$36.55

21.35%

Morgans describes FY23 results for Sonic Healthcare as "mixed" with weaker-than-expected profits and broadly in line revenue.

Management is accelerating the reduction in legacy pandemic costs, observes the broker, as reflected by FY24 guidance for earnings (EBITDA) of between $1.7-1.8bn, although full improvement for profits will take a bit longer.

Management also outlined several near-to-medium-term drivers to improve margins and profitability including acquisition synergies, fee indexation and contracts, point out the analysts.

The target falls to $36.55 from $38.96. Add.

FORECAST
Morgans forecasts a full year FY24 dividend of 109.00 cents and EPS of 140.20 cents.
Morgans forecasts a full year FY25 dividend of 114.00 cents and EPS of 163.00 cents.

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

SHL STOCK CHART

FNArena News on SHL

1
Rudi’s View: Bear&Bull Market To Continue (?) In 2024

Dec 06 2023 - Rudi's View
2
ESG Focus: The Little Big Things – 30-11-2023

Nov 30 2023 - ESG Focus
3
Australian Broker Call *Extra* Edition – Nov 24, 2023

Nov 24 2023 - Daily Market Reports
4
Rudi’s View: Quality In Stocks; What Is It Good For?

Nov 22 2023 - Rudi's View
5
ESG Focus: Day Of The TRIFRS

Nov 09 2023 - ESG Focus

Latest Healthcare services News

1
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
2
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
3
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
4
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
5
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
6
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
7
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
8
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
9
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
10
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals